ARTICLES BY LOUIS GARGUILO
-
![BioCentriqrendering]( "New Jersey Solutions For Cell And Gene Development And Manufacturing")
New Jersey Solutions For Cell And Gene Development And Manufacturing7/17/2020NJ's first university-based, cell-and-gene-therapy development and manufacturing innovation center for-hire was founded on the answers to three questions of the biopharma industry.
-
![NationwideChildrensHospital]( "U.S. Manufacturing On The Rise: Add Another CDMO To The Heartland")
U.S. Manufacturing On The Rise: Add Another CDMO To The Heartland3/16/2020Ascending U.S.-based CDMOs may exemplify a national taking back of our own supply-chain destiny. Now there’s another CDMO, Andelyn Biosciences, taking shape in Central Ohio, and targeting gene-therapy services.
-
![Harvard]( "A Harvard Assist For Cell And Gene Bottlenecks")
A Harvard Assist For Cell And Gene Bottlenecks1/27/2020Bottlenecks and backlogs in development and production of cell and gene therapies. Harvard to the rescue. Actually, Harvard with partners, such as companies familiar to Outsourced Pharma readers. But what will go into the the $50 million Center for Advanced Biological Innovation and Manufacturing? We’ve got exclusive details.
-
![375_250-pharma_equipment_monitoring]( "Equipment You Need At Your Cell-And-Gene CDMO")
Equipment You Need At Your Cell-And-Gene CDMO1/27/2020What equipment is essential at the CDMO assisting with your cell and gene therapy development and production? I’ve received some details via an investigation into Harvard’s Center for Advanced Biological Innovation and Manufacturing, and a discussion with the CEO & President of GE Healthcare Life Sciences.
-
![BeiGene Guangzhou Manufacturing Facility Design (Still in Construction)]( "Straight Talk From BeiGene On Quality, Compliance, And Outsourcing")
Straight Talk From BeiGene On Quality, Compliance, And Outsourcing1/26/2020It was time within our ruminations on China to speak directly with a quality executive at a drug developer and manufacturer based there. That’s now accomplished via a discussion with Diana Francis, Vice President, Quality & Compliance, BeiGene, Ltd., a biopharma some have dubbed as a potential “Genentech of China.” Francis spoke openly about her role, BeiGene’s global strategy, and outsourcing within and from China.
Louis Garguilo
Click here to e-mail Louis
Louis Garguilo is chief editor of Outsourced Pharma, and is considered a leading authority on the art and science of drug development and manufacturing outsourcing. He studied public relations and journalism at Syracuse University (and holds a Master’s in English). His widely read editorials are based on in-depth analysis and interviews with industry executives and professionals. Editorials are written in an engaging and unique style that guide readers through the macro aspects and subtle nuances of outsourcing, and working with contract development and manufacturing organizations (CDMOs). Garguilo also serves as moderator for the various Outsourced Pharma Live webinars held throughout the year.
Prior to joining Outsourced Pharma in 2014, Garguilo spent a decade at a global pharmaceutical contract research, development and manufacturing organization, leaving the industry after attaining the role of vice president, business development and marketing. Additionally, he has served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; as chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and communications consultant.